Welcome to our dedicated page for Organigram Global SEC filings (Ticker: OGI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) provide structured insight into the company’s operations as a Canadian cannabis cultivator and manufacturer. As a foreign private issuer, Organigram files reports such as Form 40-F and Form 6-K with the U.S. Securities and Exchange Commission. Recent Form 6-K filings reference press releases, condensed consolidated interim unaudited financial statements, management’s discussion and analysis, and officer certifications for periods including the three and nine months ended June 30, 2025.
Through these filings, readers can access detailed information on Organigram’s financial performance, including net revenue, cost of sales, gross margin, adjusted gross margin, adjusted EBITDA and free cash flow, as well as balance sheet metrics such as cash, inventories, total assets, liabilities and shareholders’ equity. The filings also discuss non-IFRS financial measures, explaining how management uses these metrics to assess the company’s financial and operational results, and provide reconciliations to IFRS figures.
Organigram’s SEC submissions frequently include news releases that cover topics such as record quarterly and annual results, acquisitions like Motif Labs Ltd. and Collective Project Limited, international sales growth, and developments in hemp-derived THC and cannabinoid beverages. They also capture governance and leadership updates, including CEO succession plans and executive appointments, and describe the company’s regulatory context under the Cannabis Act and Cannabis Regulations in Canada.
On Stock Titan’s filings page for OGI, users can review these SEC documents as they are furnished to EDGAR and use AI-powered tools to help interpret complex sections. This includes quickly identifying key themes in earnings discussions, understanding changes in non-IFRS measures, and locating disclosures related to international expansion, extraction and processing facilities, and brand portfolio developments. The filings page also offers access to current reports on Form 6-K that incorporate significant press releases, providing a consolidated view of Organigram’s regulatory and disclosure history.
BT DE Investments Inc. and related BAT entities filed Amendment No. 7 to their Schedule 13D on Organigram Global Inc., updating details of a major strategic transaction and financing. They beneficially own 40,134,389 Common Shares, representing 29.7% of that class, and 13,794,163 Class A Preferred Shares, representing all Preferred Shares, based on 135,141,944 Common Shares outstanding as of February 5, 2026.
The filing describes Organigram’s agreement to acquire all remaining shares of Sanity Group GmbH, including BAT’s stake, with BAT electing to receive Organigram equity instead of cash. BAT is expected to receive 13,693,120 Preferred Shares as upfront consideration and 6,625,559 Common Shares as potential earnout consideration, assuming full earnout at a floor price of C$3.00 per share.
To help fund the acquisition and related costs, BT DE Investments agreed to a private placement, subscribing for 14,027,074 Shares at C$3.00 per share and exercising top-up rights for 9,897,356 Shares at C$2.335854 per share. A 30% ownership threshold caps BAT’s Common Share holding; any excess is issued as non‑voting, convertible Preferred Shares with a 7.5% annual accreting conversion rate until up to 49.0% of Common Shares could be issuable on conversion, subject to regulatory, shareholder and stock exchange approvals and existing investor rights agreements.
Organigram Global Inc. entered a detailed share sale and purchase agreement to acquire all 77,349 sale shares of Sanity Group GmbH. The deal uses a fixed enterprise value of
The preliminary fixed purchase price is
The earn-out depends on post-closing financial performance and net cash, can be reduced for lower net cash, and is partly settled in cash and partly in Organigram common and preference shares, with ownership caps and regulatory conditions for key seller BAT. The agreement also sets governance, non-competition, tax, warranty and intercompany conduct rules to protect earn-out calculations.
Organigram Global Inc. filed a Form 6-K to report a change of auditor. On February 5, 2026, the board decided to terminate PKF O’Connor Davies LLP as auditor and, on February 9, 2026, determined it would propose PricewaterhouseCoopers LLP as successor auditor at the next annual general meeting.
The predecessor auditor issued unqualified opinions on Organigram’s consolidated financial statements for the years ended September 30, 2025 and 2024, but gave an adverse opinion on the effectiveness of internal control over financial reporting for those years due to material weaknesses. The notice states there have been no reportable events under National Instrument 51-102, and both PKF O’Connor Davies and PwC provided letters agreeing with the company’s descriptions of the change.
Organigram Global Inc. announced a C$65.2 million private placement from British American Tobacco’s subsidiary BAT to help fund its proposed acquisition of German cannabis company Sanity Group. BAT will subscribe for 14,027,074 shares at C$3.00 and exercise top-up rights for 9,897,356 shares at about C$2.34.
To keep BAT’s voting stake at or below 30% of Organigram’s common shares, much of the investment will be in non-voting Class A convertible preferred shares, initially convertible one-for-one and accreting at 7.5% per year until BAT and affiliates could hold up to 49% on a partially diluted basis. Based on 135,141,944 common shares outstanding, BAT is expected to receive 2,353,379 common shares and 21,571,051 preferred shares from the private placement.
Closing of both the acquisition and the financing depends on shareholder approval, Toronto Stock Exchange approval, and other regulatory clearances, including German foreign investment review. Disinterested shareholders must approve the related-party transaction under TSX rules and a "majority of the minority" vote is required under MI 61-101. The company plans to seek approvals at a March 30, 2026 meeting.
Organigram Global Inc. is expanding into Europe with a definitive deal to acquire Germany-based Sanity Group, a fast-growing medical and recreational cannabis company. Organigram will pay upfront consideration of €113.4 million, split between €80.0 million in cash and €33.4 million in Organigram shares, with potential additional earnout payments of up to €113.8 million based on Sanity’s performance.
The structure implies a total potential valuation of up to €250.0 million. Sanity’s net revenue grew from €9 million in 2023 to €60 million in 2025, with gross margins improving from 15% to 47%, and the business generated positive EBITDA in 2025. Organigram expects the deal to be financially accretive and to create a vertically integrated European hub, adding leadership positions in both Canada and the growing German medical cannabis market.
The cash portion will be funded by Organigram’s cash on hand, a new credit facility of up to $60 million with ATB Financial and lenders, and an expected C$65.2 million equity investment from British American Tobacco through a private placement and top-up rights. Closing is targeted for the second quarter of 2026, subject to shareholder approvals, TSX and German regulatory clearances, and completion of the financing arrangements.
Organigram Global Inc. reported strong growth for the quarter ended December 31, 2025, with net revenue rising to
Gross margin before fair value adjustments improved to
The company ended the quarter with
Organigram held the #1 share of the Canadian recreational cannabis market as of December 2025 and is expanding internationally, supported by a
Organigram Global Inc. will report its first quarter fiscal 2026 results, for the period ended December 31, 2025, on Tuesday, February 10, 2026, before the market opens. The company will host a conference call that day at 8:00 a.m. Eastern Time for investors and analysts.
Participants must register online to receive personalized dial-in details and access codes, and a live webcast will also be available. A replay of the webcast will be posted on Organigram’s investor website within 24 hours and remain accessible for 90 days. The filing also reiterates the company’s cannabis-focused operations in Canada and includes standard forward-looking statement cautions.
GLOBAL INC. has set key dates for its upcoming annual and special meeting of security holders. The meeting will be held on March 30, 2026, and holders of common shares on record as of February 23, 2026 will be entitled to receive notice and vote.
The meeting will cover both regular annual business and special matters. Notice-and-access will not be used for either registered or beneficial shareholders, and the issuer will pay for delivery of proxy-related materials to objecting beneficial owners.
Organigram Global Inc., a Canadian cannabis company listed on the TSX and Nasdaq under the symbol “OGI”, filed its annual report on Form 40-F as a foreign private issuer using IFRS.
The report notes 134,461,029 common shares outstanding as of the fiscal year ended September 30, 2025 and incorporates audited consolidated financial statements, management’s discussion and analysis, and an annual information form by reference.
Management determined that the company’s disclosure controls and internal control over financial reporting were not effective as of September 30, 2025 because of material weaknesses, and the independent auditor issued an adverse opinion on the effectiveness of ICFR.
The filing outlines remediation steps completed in Q4 Fiscal 2025, including engaging internal control specialists, hiring a VP of Information Technology, dedicating resources to review third‑party service organization reports and remediating certain IT general controls, and describes the board’s independent audit, compensation, governance and investment committees, code of ethics and alignment with TSX and applicable Nasdaq corporate governance standards.